Orexo concludes first clinical trial in OX51
The OX51 project aims to develop a sublingual dosage form for the treatment of acute intensive pain episodes in relation to care-related diagnostic or therapeutic procedures for patients
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi.
The licensed technology relates to the discoveries that miR-33a and miR-33b down-regulate target genes involved in cholesterol transport and genes related to metabolic syndrome. Additionally, Regulus also controls